PT - JOURNAL ARTICLE AU - Smith, David R M AU - Turner, Joanne AU - Fahr, Patrick AU - Attfield, Lauren A AU - Bessell, Paul R AU - Donnelly, Christl A AU - Gibb, Rory AU - Jones, Kate E AU - Redding, David W AU - Asogun, Danny AU - Ayodeji, Oladele Oluwafemi AU - Azuogu, Benedict N AU - Fischer, William A AU - Jan, Kamji AU - Olayinka, Adebola T AU - Wohl, David A AU - Torkelson, Andrew A AU - Dinkel, Katelyn A AU - Nixon, Emily J AU - Pouwels, Koen B AU - Hollingsworth, T Déirdre TI - Health and economic impacts of Lassa vaccination campaigns in West Africa AID - 10.1101/2024.02.26.24303394 DP - 2024 Jan 01 TA - medRxiv PG - 2024.02.26.24303394 4099 - http://medrxiv.org/content/early/2024/06/30/2024.02.26.24303394.short 4100 - http://medrxiv.org/content/early/2024/06/30/2024.02.26.24303394.full AB - Lassa fever is a zoonotic disease identified by the World Health Organization (WHO) as having pandemic potential. This study estimates the health-economic burden of Lassa fever throughout West Africa and projects impacts of a series of vaccination campaigns. We also model the emergence of “Lassa-X” – a hypothetical pandemic Lassa virus variant – and project impacts of achieving 100 Days Mission vaccination targets. Our model predicted 2.7M (95% uncertainty interval: 2.1M-3.4M) Lassa virus infections annually, resulting over ten years in 2.0M (793.8K-3.9M) disability-adjusted life years (DALYs). The most effective vaccination strategy was a population-wide preventive campaign primarily targeting WHO-classified “endemic” districts. Under conservative vaccine efficacy assumptions, this campaign averted $20.1M ($8.2M-$39.0M) in lost DALY value and $128.2M ($67.2M-$231.9M) in societal costs (International dollars 2021). Reactive vaccination in response to local outbreaks averted just one-tenth the health-economic burden of preventive campaigns. In the event of Lassa-X emerging, spreading throughout West Africa and causing approximately 1.2M DALYs within two years, 100 Days Mission vaccination averted 22% of DALYs given a vaccine 70% effective against disease, and 74% of DALYs given a vaccine 70% effective against both infection and disease. These findings suggest how vaccination could alleviate Lassa fever’s burden and assist in pandemic preparedness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Coalition for Epidemic Preparedness Innovations (CEPI) commissioned this analysis and CEPI internal Lassa fever experts were involved in study design by providing knowledge on input parameters and fine-tuning of realistic scenarios for vaccine rollout. An earlier version of this work was provided as a report to CEPI.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll underlying data and code for this article are available at www.github.com/drmsmith/lassaVac/ http://www.github.com/drmsmith/lassaVac/